Investors Yawn at Abbott Labs' Growth

I'm not exactly sure what a company has to do to get investors excited, but apparently double-digit increases in revenue and earnings aren't enough to get it done. Abbott Labs (NYSE: ABT  ) may be firing on all cylinders, but investors were less than impressed with its earnings release yesterday and sent the stock down 1.5%.

Sales were up 15%. All three divisions -- pharmaceuticals, medical products, and nutritional products -- saw double-digit growth. And Abbott was able to increase the bottom line even more. (That's something that Genentech (NYSE: DNA  ) has been having trouble doing.) The quarter's earnings per share, excluding various one-time items, were up 22% to $0.84 per share.

One reason that Abbott's stock didn't move after stellar results in a tough market environment might be that investors have come to expect the growth. Abbott's 23 earnings multiple is higher than peers Merck (NYSE: MRK  ) and Pfizer (NYSE: PFE  ) and the much larger health-care conglomerate Johnson & Johnson (NYSE: JNJ  ) . All three are in the 16 P/E range. With higher P/E comes higher expectations.

The other problem could be that, like Johnson & Johnson, Abbott has seen much of its growth fueled by international sales and currency movement. Exchange rate changes accounted for 5.9 points of the 14.8% growth in worldwide sales. When the dollar starts to climb again, a fair amount of that international growth is going to disappear.

Abbott increased both its revenue and earnings guidance for the year. One big question is how well the U.S. launch of its new drug-eluting stent, Xience V, will go. Medtronic (NYSE: MDT  ) made some good penetration in the first quarter with its stent, which, ironically, is probably a good sign for Abbott. It means that doctors are eager to try new products after having been stuck with a duopoly of J&J and Boston Scientific (NYSE: BSX  ) for so long.

Foolish investors shouldn't really worry about the short-term movement of Abbott's stock, down or up. If the company can continue its excellent growth, Abbott's stock price will follow.

Johnson & Johnson and Pfizer are both Motley Fool Income Investor recommendations. Pfizer is also a recommendation of the Inside Value newsletter. Try either of these investing newsletters free for 30 days. 

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 687206, ~/Articles/ArticleHandler.aspx, 10/25/2014 9:07:49 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 23 hours ago Sponsored by:
DOW 16,805.41 127.51 0.76%
S&P 500 1,964.58 13.76 0.71%
NASD 4,483.72 30.92 0.69%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/24/2014 4:02 PM
ABT $42.46 Up +0.03 +0.07%
Abbott Laboratorie… CAPS Rating: *****
BSX $12.99 Up +0.28 +2.20%
Boston Scientific… CAPS Rating: ***
DNA $94.97 Down +0.00 +0.00%
Genentech, Inc. CAPS Rating: ****
JNJ $103.13 Up +0.50 +0.49%
Johnson & Johnson CAPS Rating: ****
MDT $66.56 Up +0.95 +1.45%
Medtronic CAPS Rating: *****
MRK $57.61 Up +0.98 +1.73%
Merck & Co., Inc. CAPS Rating: ****
PFE $29.11 Up +0.51 +1.78%
Pfizer CAPS Rating: ****

Advertisement